Chromatomass-spectrometric determination of new antiulcer drug in rats blood plasma
T15N4
K.A. Leonov, D.A. Vishenkova, V.V. Bykov, A.A. Bakibaev
Synthesis of an innovative drug 9-(2,5-dihydroxyphenyl)-2-(4-ethoxyphenyl)-2,3,7,8-tetrahydro-1H-pyrido [1,2-a] pyrazine-1,4(6H)-dione (PPI) for the treatment of peptic ulcer with a new mechanism of action has necessitated the pharmacokinetics study of the substance in the blood plasma and investigation of its absorption and elimination processes. This paper describes the development and validation of a technique for quantitative determination of the new compound PPI in rat blood plasma by HPLC/MS. The method of solid-phase extraction is applied to extract PPI from blood plasma in the process of biological samples preparation. The lower limit of quantification is 0.1 ng ml–1, the linearity range from 0.1 to 1000 ng ml–1. By the developed technique the sample analysis of rats blood plasma was carried out after pharmaceutical PPI substance introduction in a dose of 20 mg kg–1, a pharmacokinetic profile of the substance was established, and pharmacokinetic parameters were calculated that allows one to judge the degree and rate of absorption and excretion of new antiulcer drug in the blood of laboratory rats.